HIMS Stock: Buy the Dip or Avoid the Margin Squeeze?
💡 Puntos Clave
Hims & Hers Health's pivot to weight-loss drugs is boosting revenue but crushing near-term profitability, making the stock a high-risk, speculative bet.
What Happened to Hims & Hers?
Hims & Hers Health stock is on a rollercoaster, having halved in value over the past year. Following its Q1 2025 earnings report, the stock headed lower again. The company raised its full-year revenue forecast but delivered a major warning on profits.
Management now expects 2026 revenue of $2.8B-$3.0B, up from prior guidance, but slashed its adjusted EBITDA forecast to $275M-$350M, down from $300M-$375M. This profit guidance cut is the core of the stock's recent weakness.
The shift is driven by a strategic pivot into branded weight-loss drugs like Novo Nordisk's Wegovy. This move is attracting new subscribers and boosting top-line sales, but these products come with significantly lower profit margins for Hims.
In Q1, results highlighted this trade-off: revenue grew a modest 4% to $608.1M, adjusted EBITDA plummeted 51%, and the company posted a per-share loss compared to a profit a year ago. Subscriber growth was positive, but revenue per subscriber declined.
Why This Earnings Shift Matters
For investors, this isn't just a quarterly miss; it's a potential change in the company's investment narrative. Hims has been valued as a high-growth telehealth disruptor, but margin compression challenges that story.
Stocks valued on growth typically need expanding profits, not just rising sales. A guidance cut for a key profitability metric like EBITDA signals the business model is under pressure as it scales into new, lower-margin categories.
The company's bet is that it can offset these lower margins over time through cross-selling higher-margin products and achieving greater scale. However, this is an unproven strategy in the competitive weight-loss market.
Finally, the article points to peptides as a potential future catalyst. If the FDA approves these compounds, it could reignite growth. But this is highly speculative, as peptides are currently restricted and their regulatory path is uncertain, adding another layer of risk.
Fuente: The Motley Fool
Análisis generado por el modelo cuantitativo de Bobby AI, revisado y editado por nuestro equipo de investigación. Esto no constituye asesoramiento financiero. Investigue por su cuenta antes de tomar decisiones de inversión.
Bobby Insight
Avoid the dip unless you're making a purely speculative bet on FDA peptide approval.
The core growth story is deteriorating as revenue gains come at the expense of profitability. While the peptide opportunity exists, it's too uncertain and regulatory-dependent to justify an investment based on the company's current fundamentals.
¿Cómo Me Afecta?
